|Articles|October 1, 2012

Retrospective: CleanRooms_Dixon

To view a PDF of this article from the BioPharm International archives, click this link

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies

By4basebio

November 19th 2025

Survey: Biopharma Impacts of the Commissioner's National Priority Vouchers Program

ByChristopher Cole

November 14th 2025

Cancer cells forming a solid tumor mass, with detailed cell structure and environment | Image credit: © Ummeya - © Ummeya - stock.adobe.com

In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges

ByFeliza Mirasol

November 6th 2025

Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization

ByFeliza Mirasol

October 31st 2025

BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints

ByEric Langer

October 31st 2025

Retrospective: CleanRooms_Dixon

Newsletter

Related Content

The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies

Survey: Biopharma Impacts of the Commissioner's National Priority Vouchers Program

In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges

Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization

BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints

Trending on BioPharm International

Implications of the First Liquid IV Infliximab Biosimilar

Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program

Why 503B Compounding Pharmacies Choose Prefabricated POD® Cleanrooms

The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies

Integrated Services for the Whole Drug Development Pathway